Form D · Pharmaceuticals

DalCor Pharmaceuticals US, LLC

Sarasota, FL · CIK 0001673368

Offering snapshot reported Aug 28, 2026 · SEC filing

Reported sold
$6.96M
Offering amount: $6.96M
Investors reported
8
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jul 30, 2026
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Aug 28, 2026Initial$6,958,236No comparison8SEC filing
Sep 14, 2020Amendment$3,851,699$2,515,395vs May 27, 20204SEC filing
May 27, 2020Initial$1,336,304No comparison4SEC filing
May 12, 2017Amendment$55,000,000$38,500,000vs May 13, 201647SEC filing
May 13, 2016Initial$16,500,000No comparison44SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-595783

Source: Form D, filed Aug 28, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Thomas Birch Director
Donald Black Director
Douglas Michael Dixon Director
D. Michael Dixon Director, Executive
D. Michael Dixon Director
Paul Fonteyne Director
Ga?Tan Gravel Director
Didier Leconte Director
Robert Mc Neil Director, Executive, Promoter
Louise Proulx Executive
Laurence Rulleau Director
Mark Smith Director
Rody Yared Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
677 North Washington Blvd Suite 132
Sarasota, FL, 34236
Phone: 514 508-5099